These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 11256075)

  • 21. Pharmacogenomics: will the regulators approve?
    Hodgson J; Marshall A
    Nat Biotechnol; 1998 Mar; 16(3):243-6. PubMed ID: 9528002
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacogenomics: questions and concerns.
    Mahlknecht U; Voelter-Mahlknecht S
    Curr Med Res Opin; 2005 Jul; 21(7):1041-7. PubMed ID: 16004671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 24. Surviving the blockbuster syndrome.
    Service RF
    Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
    [No Abstract]   [Full Text] [Related]  

  • 25. The coming pharmacogenomics revolution: tailoring drugs to fit patients' genetic profiles.
    Noah L
    Jurimetrics; 2002; 43(1):1-28. PubMed ID: 17333591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ethical, social and legal issues in pharmacogenomics.
    Wertz DC
    Pharmacogenomics J; 2003; 3(4):194-6. PubMed ID: 12931132
    [No Abstract]   [Full Text] [Related]  

  • 28. The drug diagnostic co-development concept paper: commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop.
    Hinman LM; Huang SM; Hackett J; Koch WH; Love PY; Pennello G; Torres-Cabassa A; Webster C
    Pharmacogenomics J; 2006; 6(6):375-80. PubMed ID: 16652120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacogenomics.
    Tribut O; Lessard Y; Reymann JM; Allain H; Bentué-Ferrer D
    Med Sci Monit; 2002 Jul; 8(7):RA152-63. PubMed ID: 12119546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
    Wang SJ
    Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenomics: bench to bedside.
    Weinshilboum R; Wang L
    Nat Rev Drug Discov; 2004 Sep; 3(9):739-48. PubMed ID: 15340384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of pharmacogenomics.
    Somogy A
    Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug discovery and development in the age of molecular medicine.
    Vallance P; Levick M
    Clin Pharmacol Ther; 2007 Oct; 82(4):363-6. PubMed ID: 17851574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein therapeutics: new applications for pharmacogenetics.
    Krejsa C; Rogge M; Sadee W
    Nat Rev Drug Discov; 2006 Jun; 5(6):507-21. PubMed ID: 16763661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenomics - therapeutic and ethical issues.
    Patowary S
    Kathmandu Univ Med J (KUMJ); 2005; 3(4):428-30. PubMed ID: 16449851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global requirements for DNA sample collections: results of a survey of 204 ethics committees in 40 countries.
    Ricci DS; Broderick ED; Tchelet A; Hong F; Mayevsky S; Mohr DM; Schaffer ME; Warner AW; Hakkulinen P; Snapir A
    Clin Pharmacol Ther; 2011 Apr; 89(4):554-61. PubMed ID: 21346753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics: the Rx perspective.
    Renegar G; Rieser P; Manasco P
    Expert Rev Mol Diagn; 2001 Sep; 1(3):255-63. PubMed ID: 11901830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ethical implications of stratifying by race in pharmacogenomics.
    Lee SS
    Clin Pharmacol Ther; 2007 Jan; 81(1):122-5. PubMed ID: 17186010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of pharmacogenomics for drug development and clinical practice.
    Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
    Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.